These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29245294)

  • 1. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
    Jung M; Park SH; Jeon YK; Won JK; Yang HK; Kim WH
    Medicine (Baltimore); 2017 Dec; 96(49):e9031. PubMed ID: 29245294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.
    Jang BG; Lee HE; Kim WH
    Virchows Arch; 2015 Oct; 467(4):393-403. PubMed ID: 26243012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib.
    Brown JB; Pai RK; Burgess MA; Chennat J; Zureikat AH
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1424-1428. PubMed ID: 30545989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
    Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
    Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
    Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
    Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Ali Abuderman AW; M Aldakheel F
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation.
    Jones DH; Caracciolo JT; Hodul PJ; Strosberg JR; Coppola D; Bui MM
    Cancer Control; 2015 Jan; 22(1):102-8. PubMed ID: 25504284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
    Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
    Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy.
    Vassos N; Agaimy A; Schlabrakowski A; Hohenberger W; Schneider-Stock R; Croner RS
    Virchows Arch; 2011 Mar; 458(3):363-9. PubMed ID: 21191613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors.
    Kang GH; Srivastava A; Kim YE; Park HJ; Park CK; Sohn TS; Kim S; Kang DY; Kim KM
    Mod Pathol; 2011 Jun; 24(6):866-75. PubMed ID: 21358619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
    Miettinen M; Wang ZF; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1401-8. PubMed ID: 19606013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach.
    Wada T; Tanabe S; Ishido K; Higuchi K; Sasaki T; Katada C; Azuma M; Naruke A; Kim M; Koizumi W; Mikami T
    World J Gastroenterol; 2013 Dec; 19(47):9133-6. PubMed ID: 24379641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
    Antonescu CR; Romeo S; Zhang L; Nafa K; Hornick JL; Nielsen GP; Mino-Kenudson M; Huang HY; Mosquera JM; Dei Tos PA; Fletcher CD
    Am J Surg Pathol; 2013 Mar; 37(3):385-92. PubMed ID: 23348204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma.
    Riddle ND; Gonzalez RJ; Bridge JA; Antonia S; Bui MM
    Cancer Control; 2011 Jul; 18(3):152-9. PubMed ID: 21666577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
    Bosbach B; Deshpande S; Rossi F; Shieh JH; Sommer G; de Stanchina E; Veach DR; Scandura JM; Manova-Todorova K; Moore MA; Antonescu CR; Besmer P
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):E2276-83. PubMed ID: 22652566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
    Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
    Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.